These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 32589369)
21. Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure. Huusko J; Tuominen S; Studer R; Corda S; Proudfoot C; Lassenius M; Ukkonen H ESC Heart Fail; 2020 Oct; 7(5):2406-2417. PubMed ID: 32667143 [TBL] [Abstract][Full Text] [Related]
22. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458 [TBL] [Abstract][Full Text] [Related]
23. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. Roy C; Lejeune S; Slimani A; de Meester C; Ahn As SA; Rousseau MF; Mihaela A; Ginion A; Ferracin B; Pasquet A; Vancraeynest D; Beauloye C; Vanoverschelde JL; Horman S; Gruson D; Gerber BL; Pouleur AC ESC Heart Fail; 2020 Oct; 7(5):2494-2507. PubMed ID: 32578967 [TBL] [Abstract][Full Text] [Related]
24. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China]. Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275 [No Abstract] [Full Text] [Related]
25. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Lam CSP; Gamble GD; Ling LH; Sim D; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Cameron VA; Poppe K; Lund M; Devlin G; Troughton R; Richards AM; Doughty RN Eur Heart J; 2018 May; 39(20):1770-1780. PubMed ID: 29390051 [TBL] [Abstract][Full Text] [Related]
26. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Rabkin SW; Tang JKK Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523 [TBL] [Abstract][Full Text] [Related]
27. Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD). Claus R; Berliner D; Bavendiek U; Vodovar N; Lichtinghagen R; David S; Patecki M; Launay JM; Bauersachs J; Haller H; Hiss M; Balzer MS Clin Res Cardiol; 2020 Aug; 109(8):1035-1047. PubMed ID: 32002632 [TBL] [Abstract][Full Text] [Related]
28. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. Moliner P; Lupón J; Barallat J; de Antonio M; Domingo M; Núñez J; Zamora E; Galán A; Santesmases J; Pastor C; Bayes-Genis A Int J Cardiol; 2018 Apr; 257():188-192. PubMed ID: 29415801 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction. Song Y; Li F; Xu Y; Liu Y; Wang Y; Han X; Fan Y; Cao J; Luo J; Sun A; Hu K; Zhou J; Ge J Int J Cardiol; 2020 Apr; 304():95-100. PubMed ID: 32019693 [TBL] [Abstract][Full Text] [Related]
30. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Izumiya Y; Hanatani S; Kimura Y; Takashio S; Yamamoto E; Kusaka H; Tokitsu T; Rokutanda T; Araki S; Tsujita K; Tanaka T; Yamamuro M; Kojima S; Tayama S; Kaikita K; Hokimoto S; Ogawa H Can J Cardiol; 2014 Mar; 30(3):338-44. PubMed ID: 24484911 [TBL] [Abstract][Full Text] [Related]
31. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760 [TBL] [Abstract][Full Text] [Related]
32. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction. Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958 [TBL] [Abstract][Full Text] [Related]
33. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Baessler A; Strack C; Rousseva E; Wagner F; Bruxmeier J; Schmiedel M; Riegger G; Lahmann C; Loew T; Schmitz G; Fischer M Eur J Heart Fail; 2012 Nov; 14(11):1240-8. PubMed ID: 22843563 [TBL] [Abstract][Full Text] [Related]
34. GDF-15: a novel biomarker of heart failure predicts short-term and long-term heart-failure rehospitalization and short-term mortality in patients with acute heart failure syndrome. Kosum P; Siranart N; Mattanapojanat N; Phutinart S; Kongruttanachok N; Sinphurmsukskul S; Siwamogsatham S; Puwanant S; Ariyachaipanich A BMC Cardiovasc Disord; 2024 Mar; 24(1):151. PubMed ID: 38475710 [TBL] [Abstract][Full Text] [Related]
35. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction. Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226 [TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. Shiga T; Suzuki A; Haruta S; Mori F; Ota Y; Yagi M; Oka T; Tanaka H; Murasaki S; Yamauchi T; Katoh J; Hattori H; Kikuchi N; Watanabe E; Yamada Y; Haruki S; Kogure T; Suzuki T; Uetsuka Y; Hagiwara N; ESC Heart Fail; 2019 Jun; 6(3):475-486. PubMed ID: 30829002 [TBL] [Abstract][Full Text] [Related]
37. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Rickenbacher P; Kaufmann BA; Maeder MT; Bernheim A; Goetschalckx K; Pfister O; Pfisterer M; Brunner-La Rocca HP; Eur J Heart Fail; 2017 Dec; 19(12):1586-1596. PubMed ID: 28295985 [TBL] [Abstract][Full Text] [Related]
38. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866 [TBL] [Abstract][Full Text] [Related]
39. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E Circulation; 2011 May; 123(19):2101-10. PubMed ID: 21536998 [TBL] [Abstract][Full Text] [Related]
40. Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure. Gürgöze MT; van Vark LC; Baart SJ; Kardys I; Akkerhuis KM; Manintveld OC; Postmus D; Hillege HL; Lesman-Leegte I; Asselbergs FW; Brunner-la-Rocca HP; van den Bos EJ; Orsel JG; de Ridder SPJ; Pinto YM; Boersma E Circ Heart Fail; 2023 Jan; 16(1):e009526. PubMed ID: 36408685 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]